CD274 and non-small cell lung carcinoma: Notable examples of FDA approved PD-L1 inhibitors include atezolizumab for metastatic non-small cell lung cancer (NSCLC)21 and durvalumab for locally advanced or metastatic urothelial carcinoma22.